A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Phase of Trial: Phase IV
Latest Information Update: 20 May 2017
Price : $35 *
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Amgen
- 30 May 2016 Status changed from active, no longer recruiting to completed.
- 13 Oct 2015 Planned End Date changed from 1 Apr 2017 to 1 May 2016, as reported by ClinicalTrials.gov.
- 13 Oct 2015 Planned primary completion date changed from 1 Oct 2016 to 1 May 2016, as reported by ClinicalTrials.gov.